Strength training earns its place in a lever list on two claims: it lowers mortality and major disease
independently of aerobic activity, and it does so at a small dose. Three meta-analyses now
converge on this — Momma 2022 (broad muscle-strengthening activity), Saeidifard 2019 and Shailendra 2022
(both framed as resistance training). But all three pool mostly the same US self-report cohorts (Momma
explicitly compares itself to Saeidifard; Shailendra explicitly «builds on» Saeidifard, adding 9 studies
to the same evidence base; and the mortality data are largely the same NHANES/NHIS/pooled-cohort
muscle-strengthening pools) — so the later MAs are refinements, not independent corroboration (type-F,
not [E-independent]), and the evidence stays observational, self-reported, higher/very-high risk of bias
on the exposure. A real but weakly-warranted lever, held one tier below the RCT-grade BP and lipid
evidence — three concordant re-poolings of one shared cohort base do not raise its certainty above
low. What the mortality-specific MAs add is endpoint resolution and dose, not independence:
Saeidifard and Shailendra both isolate cardiovascular mortality (borderline, CI touches 1) from Momma’s
CVD incidence (significant); and Shailendra’s larger cancer pool (5 studies vs Saeidifard’s 2) turns
the earlier null cancer-mortality estimate significant — a precision gain on a shared direction, not
a reversal (see the cross-source table below).
The effects — modest, broad, and independent of aerobic exercise
Any muscle-strengthening activity (MSA) vs none, «independent of aerobic activities»:
| Outcome | RR (95% CI) | GRADE |
|---|---|---|
| All-cause mortality | «RR 0.85; 95% CI 0.79 to 0.93» (−15%) | very low |
| Cardiovascular disease | «RR 0.83; 95% CI 0.73 to 0.93» (−17%) | very low |
| Total cancer | «0.88 (0.80 to 0.97)» (−12%) | very low |
| Diabetes | «0.83 (0.77 to 0.89)» (−17%) | low |
The independence matters: these are adjusted for aerobic activity, and combined MSA + aerobic gives a much larger benefit — «a 40% lower risk of all-cause mortality (RR 0.60; 95% CI 0.54 to 0.67)» — so strength and aerobic are additive, not substitutes. This corroborates and refines the held strength-guideline finding on Physical Activity Dose and Mortality (both-guideline HR ~0.71); it is not independent backing (same observational PA-epidemiology lineage, overlapping US cohorts), so it is a refinement, not an [E-independent] convergence.
Saeidifard 2019 — the second MA, endpoint-resolved and mortality-specific
Saeidifard is a SR-MA of «11 (one randomized trial and 10 cohort studies)… totaling 370,256 participants with mean follow-up of 8.85 years», restricted to studies its authors label resistance training (defined «typically at loads greater than 65% of the one-repetition maximum»). It asks the mortality-specific question Momma’s broad MSA-and-disease pool does not isolate:
| Outcome (RT vs no exercise) | HR (95% CI) | Note |
|---|---|---|
| All-cause mortality | «0.79 (0.69–0.91)» (−21%) | significant |
| Combined RT + aerobic vs no exercise | «0.60 (0.49–0.72)» (−40%) | additive; larger than either alone |
| Cardiovascular mortality | «0.83 (0.67–1.03)» (abstract) / «0.83 (0.68–1.01)» (Fig 3a) | borderline — CI crosses 1 |
| Cancer mortality | «0.81 (0.54–1.20)» | no significant association |
| CHD events, men (1 cohort, n=44,452, 2y) | «RR 0.77… CI: 0.61–0.98» (−23%) | «trained with weights for 30 min or more per week»; one study only |
Two decision-relevant refinements over Momma:
- The CV benefit is softer on the harder endpoint. Momma’s «RR 0.83; 95% CI 0.73 to 0.93» is CVD incidence (significant); Saeidifard’s identical 0.83 point estimate is CV mortality and its CI crosses 1 — so acting on the CV-mortality claim specifically rests on a borderline association, not the clean incidence signal. Same number, different (harder) endpoint, weaker warrant.
- Cancer: incidence favourable, mortality null. Momma finds total-cancer incidence «0.88 (0.80 to
0.97)»; Saeidifard finds cancer mortality «0.81 (0.54–1.20)», non-significant. These are different
endpoints, not a contradiction — RT’s cancer value (if any) is plausibly on incidence and on
cancer-patient function/lean-mass, not on lowering death-from-cancer, which the data cannot show.
- Superseded on the mortality leg (Shailendra 2022): Saeidifard’s cancer-mortality null rested on only 2 studies; Shailendra pools 5 and finds cancer mortality «0.86 (0.78, 0.95)», significant — a precision gain on the same direction (point estimates 0.81 vs 0.86), not a reversal. So the “mortality null” is now read as an underpowered null, not a real absence of effect: RT’s cancer signal appears on both incidence (Momma) and mortality (Shailendra), still observational and self-reported. See the Shailendra section and the 3-way table below.
Dose. Saeidifard’s own reading matches Momma’s caution against the upper arm: performing «>0 to two sessions of resistance training per week is associated with lower all-cause mortality (0.79 (0.66–0.95)), but doing more than two sessions of resist-ance training is not», and «2–3 sessions… is not significantly better than… lower frequencies… (1.00 (0.89–1.11))». The authors suggest optimal benefit «by 1–2 sessions per week and avoiding high-intensity low-repe-tition type activities» but explicitly disown a firm shape: «the current evidence is not enough to conclude that the relationship between resistance training and survival has a U-shape curve.» This is a second-source corroboration of the The U-Shaped Association Artifact reading — the upper arm is not believed by either MA.
Shailendra 2022 — the third MA: a larger cancer pool and a minutes/week dose curve
Shailendra is the mortality-specific update of Saeidifard: a SR-MA of 10 prospective cohort studies (all self-reported RT, follow-up 7-17 years, ages 18-85, all but two US), restricted to nonclinical adults and to the three mortality endpoints. It explicitly «builds on» Saeidifard by adding 9 studies, so it is a type-F refinement of the same evidence base, not independent backing.
| Outcome (any RT vs none) | RR (95% CI) | n studies | Note |
|---|---|---|---|
| All-cause mortality | «0.85; 95% CI=0.77, 0.93» (−15%) | 6 | significant (Results/Table 1 read 0.77, 0.94 — a 0.01 internal discrepancy) |
| CVD mortality | «0.81; 95% CI=0.66, 1.00» (−19%) | 4 | borderline — CI touches 1.00 (Table 1 misprints the lower bound as 0.61) |
| Cancer mortality | «0.86; 95% CI=0.78, 0.95» (−14%) | 5 | significant — the endpoint Saeidifard’s 2-study pool left null |
Highest-vs-lowest is attenuated to null for mortality. The «some vs none» contrast above captures the signal; comparing the highest RT level with the lowest washes it out — all-cause «0.92; 95% CI=0.83, 1.01» (NS), CVD «0.90; 95% CI=0.79, 1.02» (NS), cancer «0.87; 95% CI=0.77, 0.99» (barely significant). This mirrors the diminishing-at-higher-volumes dose-response below: doing some is where the benefit lives; doing much more adds little. (Shailendra et al., 2022)
The dose-response — a third nonlinear curve, nadir ~60 min/week, upper arm on 4 studies. A 1-stage restricted-cubic-spline dose-response MA (knots at 10/30/150 min) of the 4 studies reporting minutes/week found a nonlinear «U»-shaped curve: «a maximum risk reduction of 26% observed at around 60 minutes per week of resistance training (RR=0.74; 95% CI=0.64, 0.86)», with «Mortality risk reductions dimin- ished at higher volumes than 60 minutes per week». (The source states this maximum inconsistently — 26% in Results (matching RR 0.74), 27% in the Abstract, and 33% in the Discussion; the unambiguous anchor is RR 0.74, 0.64-0.86 at ~60 min/week.) The authors themselves urge caution: the curve «only included 4 studies, it should be viewed with caution». (Shailendra et al., 2022)
(inferred from Shailendra et al., 2022) This is a third instance of the The U-Shaped Association Artifact reading, converging with Momma’s 40 min/week J-shape: the lower arm (benefit acquired by a small weekly volume, ~40-60 min) is believable; the upper «U» arm — more is worse past ~60 min/week — rests on only 4 studies, with the spline’s upper knot at 150 min (the 90th percentile) so the rising segment sits in the sparse-data tail. That is exactly the unequal-precision / sparse-tail region the artifact concept warns against, and the point-optimum «~60 min/week» is a wide imprecise region, not a target (the studied range and the 4-study base are its two load-bearing caveats). Do not act on the upper arm; do not chase or fear high RT volume for mortality — the decision-relevant claim is the lower arm.
Joint RT + MVPA — the triple 0.60 convergence. Performing both vs neither gives «by 40% (RR=0.60; 95% CI=0.54, 0.66)» lower all-cause mortality — matching Momma’s «0.60 (0.54 to 0.67)» and Saeidifard’s «0.60 (0.49–0.72)» essentially exactly. Striking, but F not E: shared cohorts (Stamatakis, Kamada, Zhao in all the joint pools), so the convergence is the same finding re-pooled, not three independent roads to 0.60. (Shailendra et al., 2022)
Exposure quality is the binding limit. «All the 10 included studies were found to have a higher risk
or very high risk of bias in the way the exposure» was measured — self-reported (all 10), single-timepoint
(8 of 10), no validated instrument (none), RT prevalence 9-27% across cohorts, heterogeneity I2 up to ~80%. The measurement
constraint is why only 4 of 10 studies could enter the dose-response, and it caps the whole cluster at
low confidence. (Shailendra et al., 2022)
(inferred from Momma et al., 2022; Saeidifard et al., 2019; Shailendra et al., 2022)
The three MAs compared — same lever, mostly the same cohorts (type-F, not type-E)
The op-weave parameter table, with the same-quantity column doing the work:
| Parameter | Momma 2022 | Saeidifard 2019 | Shailendra 2022 | Same quantity? |
|---|---|---|---|---|
| Exposure | broad MSA | labelled RT (>65% 1RM), cohorts mostly same MSA self-report | labelled RT, all self-report; mixed MSA/weight-lifting/strength wording | NO — all three run on the same self-report MSA instrument; “RT-specific” framing not carried by the data |
| Metric | RR | HR (OR→RR) | RR | ~ all hazard-type; comparable |
| All-cause mort. | «0.85 (0.79 to 0.93)» −15% | «0.79 (0.69–0.91)» −21% | «0.85; 95% CI=0.77, 0.93» −15% | Same construct, overlapping pools (not independent) |
| Combined + aerobic → all-cause | «0.60 (0.54 to 0.67)» | «0.60 (0.49–0.72)» | «0.60; 95% CI=0.54, 0.66» | Triple point convergence, but F not E (shared cohorts) |
| CVD mort. | «0.83 (0.73 to 0.93)» — incidence, sig | «0.83 (0.67–1.03)» — mortality, borderline | «0.81; 95% CI=0.66, 1.00» — mortality, CI touches 1 | Momma = incidence; both RT MAs = mortality, both borderline |
| Cancer mort. | «0.88 (0.80 to 0.97)» — incidence, favourable | «0.81 (0.54–1.20)» — mortality, null (2 studies) | «0.86; 95% CI=0.78, 0.95» — mortality, sig (5 studies) | Same endpoint across the RT MAs; the null was underpowered, now resolved sig — a precision gain, not a reversal |
| Dose | J-shape, nadir «40 min/week» | «>0 to two sessions/wk» sig, >2 not; U disowned | «U»-shape, nadir ~60 min/wk (RR 0.74, 0.64-0.86, 4 studies); diminishing above | Related nonlinear shape; Momma & Shailendra both in minutes/wk, ~40-60 min nadir |
The cancer-mortality cell is the one genuine refinement (F): Saeidifard’s null and Shailendra’s significant estimate are the same quantity (RT → cancer mortality, RR), and the flip is driven by study count (2 → 5), point estimates staying in the 0.81-0.86 band — a precision gain, not a contradiction to file as a tension. Every other cell is either the same finding re-pooled (F) or a different endpoint (a distinction), so no cell survives as an [E-independent] convergence.
Independence: type-F (refinement) across all three, not [E-independent]. Three defeaters, any one sufficient:
- Each later MA cites its predecessor. Momma positions itself against Saeidifard/Nascimento; Shailendra explicitly «builds on» Saeidifard, adding 9 studies to the same base. A later MA that names and refines an earlier one is F by construction.
- Shared constituent cohorts. Saeidifard’s pool (Dankel, Kamada, Zhao, Kraschnewski, Loprinzi, Schoenborn, Evenson…) and Shailendra’s 10 (Stamatakis, Kamada, Zhao, Liu, Patel, Siahpush, Sheehan, Nie, Porter, Hsu) draw on the same NHANES/NHIS/pooled-cohort MSA-mortality lineage Momma pools — Kamada and the NHIS/NHANES families recur across all three. Pooling the same data thrice is not three independent tests (the volume-is-not-independence rule). Shailendra even excluded 9 studies for «overlapping samples», keeping the largest — an internal de-duplication that does nothing to make it independent of the earlier reviews over the same cohorts.
- Same instrument, same confounding structure — self-reported muscle-strengthening frequency, all studies rated higher/very-high risk of bias on the exposure.
So the triple 0.60 combined convergence, however striking, does not raise confidence; it is the same
finding re-pooled. No [E-independent] stamp — the cluster stays low.
The dose — small, and a J-shape whose upper arm should not be believed yet
The dose-response is the interesting part, and it is a worked case for The U-Shaped Association Artifact:
«J-shaped associations were found between muscle-strengthening activities and all-cause mortality, CVD and total cancer, with the maximum risk reduction (approximately 10–20%) at approximately 30–60 min/week»
The pooled nadir is «The lowest RR (RR 0.83; 95% CI 0.79 to 0.86)… at 40 min/week», with benefit persisting to ~130-140 min/week and the hazard then rising above 1.0 — the J’s upper arm, suggesting more is worse past ~2 hours/week.
Two cautions on that «40 min/week», because the point is fragile and easy to over-read
[user-challenge 2026-07-29]:
- The optimum is a wide, imprecise region, not 40 minutes. Momma’s own headline is a range («approximately 30–60 min/week»), and a key constituent study puts it higher: «the lowest risk of all-cause mortality was observed at 82 min/week of strength training» (Kamada). On very-low-GRADE, sparse, self-reported data the single pooled point (40) should be read as somewhere in the ~30–80+ min/week region, not a precise target.
- This is total weekly MINUTES, not FREQUENCY — Momma «could not directly examine the frequency of muscle-strengthening activities». So the curve says nothing about 2x vs 3x/week or session spacing; 40 min/week could be two 20-minute sessions as easily as one. In particular it does not speak to the training-physiology heuristic of stimulating each muscle group every ~48 h — that is advice for muscle/strength adaptation (hypertrophy, protein synthesis), a different outcome on a different evidence base -> Protein and Resistance Training for Muscle and Strength (Morton 2018, now held: RT is the driver, protein a modest RCT-grade adjunct up to ~1.6 g/kg/day). The mortality dose-response and the strength-adaptation question are two things, and this source answers only the first.
Do not act on the upper arm. Three reasons it is likely an artifact, not a dose feature:
- The authors disown it: «the influence of a higher volume… on all-cause mortality, CVD and total cancer is unclear, considering the observed J-shaped associations»; «a higher volume may require caution» — a hedge, not a finding.
- The evidence cannot bear it: «very low» GRADE, «only a small number of studies», self-reported exposure, sparse data at high volumes, and publication bias untestable («pooled estimates… might have been overestimated»). The upper arm is exactly the unequal-precision / reverse-causation region The U-Shaped Association Artifact warns about.
- The built-in counter-instance: for diabetes the same exposure is L-shaped, not J — «the
risk of diabetes sharply decreasing until up to 60 min/week… followed by a gradual decrease», no
upturn, and with a clear muscle-glucose mechanism. The same MSA cannot protect monotonically for
diabetes and turn harmful for mortality at high volume unless the mortality upturn is a measurement or
confounding artifact.
- What the muscle-glucose mechanism IS (Challenge #24, average adult): skeletal muscle is the principal site of insulin-stimulated glucose disposal, so building and using muscle enlarges the body’s glucose «sink» and improves glucose tolerance. This makes resistance training a glycaemic lever, not only a function/mortality one — decision-relevant specifically for the dysglycaemic / metabolic-syndrome stratum (the drifting-median adult), where the held diabetes L-shape is the outcome this mechanism produces. The exposure whose mechanism is clear (diabetes) shows no upturn; the outcomes whose upturn lacks a mechanism (mortality/CVD/cancer) show one — the diagnostic signature of an artifactual arm.
What survives: the lower arm — a real, modest benefit reached by a modest weekly volume (a wide, imprecise ~30-80+ min/week region; the standard «at least 2 days/week» sits comfortably inside it). What does not: any reason to fear or to chase high MSA volume for mortality — nor any reading of an optimal frequency, which this source cannot supply.
Decision relevance
- Add strength training — a modest weekly volume reaches most of the mortality benefit (~30-80+ min/week, imprecise; the standard «at least 2 days/week» is inside it), and it adds benefit on top of aerobic (the two combined are the best-evidenced activity state). The effective volume is small; the optimal frequency / spacing (e.g. every ~48 h) is a strength-adaptation question this mortality evidence does not address.
- But weight the warrant honestly. This is observational, self-reported, very-low-GRADE evidence — a plausible, directionally-robust association, not an RCT-grade effect. It belongs below the BP and aerobic-activity levers in certainty, not above.
- For fitness (VO2max) it is complementary, not the same lever. Strength training raises strength and lean mass; aerobic/interval work raises CRF (Measuring and Raising Cardiorespiratory Fitness). Both belong in an untrained person’s program.
(inferred from Momma et al., 2022)
The healthspan case is stronger than the mortality case — it runs through function and falls (Challenge #17)
The very-low certainty above is for one endpoint — muscle-strengthening -> all-cause mortality (Momma, self-reported, observational). It is not the verdict on strength training’s healthspan value, which runs through better-evidenced channels:
- Function and falls are held, patient-important, and stronger. Physical activity in older adults reduces falls, injurious falls, and probably fractures — outcomes people care about directly, not surrogates, and the strongest outcome class the annex carries for this stratum (Physical Activity Dose and Mortality, WHO PA annex). Avoiding a fall/fracture and keeping physical function is the healthspan payoff, and it is graded above the mortality signal. (Caveat: the held evidence is for exercise broadly; falls-prevention specifically combines resistance + balance training, which the wiki holds at the activity level, not RT-specifically -> a gap.)
- Grip strength and muscle mass are strong mortality PREDICTORS — now held, and still predictors, not proof. Low grip strength tracks all-cause and cause-specific mortality (Celis-Morales 2018, UK Biobank n=502,293: all-cause HR 1.16-1.20 per 5 kg lower grip; ~1.48 per 1 SD, out-ranking SBP and total activity in-model) -> Grip Strength and Mortality; low muscle mass likewise -> Low Muscle Mass and Mortality. But both are the same predictor-vs-cause gap as fitness (Cardiorespiratory Fitness and Mortality): a strong predictor does not prove the intervention (resistance training) moves the outcome — grip is heritable (~52%) and disease-sensitive, so it is part marker, part lever. The strength-training mortality evidence remains this page’s very-low-GRADE number.
So strength training’s weak card is the mortality evidence; its strong card is function/falls (held) plus the muscle-mass/strength predictor literature (unheld). For an older or sarcopenia-risk stratum the case is stronger than the very-low mortality number alone implies — the lever’s value is in keeping function and staying off the floor, not (on current evidence) a proven mortality reduction.
- And the kind of resistance training matters for that function card. Power Training and Physical Function in Older Adults (el Hadouchi 2022, gold SR+MA) adds a GRADE-HIGH functional result to this strong card: for older adults, a velocity/power emphasis beats conventional heavy-load strength on the activity-test outcomes (generic-function SMD 0.43, speed-emphasis 0.36) — specifying not just that strength training defends function but how to train for maximum functional payoff in this stratum. (inferred from el Hadouchi et al., 2022)
Limits
- One meta-analysis, observational, «very low» GRADE; mostly US cohorts; self-reported exposure; high heterogeneity (I2 up to 83%); publication bias untestable.
- The dose-response upper arm is not usable (above); the diabetes L-shape is the more trustworthy dose curve.
- Frequency vs total-time could not be separated; the target-dose is a region, not a number.
(inferred from Momma et al., 2022)
Why the diabetes curve is clean but the mortality curve is not (deliverable-critique, 2026-08-01)
A reasonable puzzle (deliverable-critique): how can the diabetes dose-response be clean and L-shaped while all-cause mortality is noisy - does glycaemic control not reach mortality? It does: RT lowers both (mortality RR 0.85, diabetes 0.83), so the glycaemic lever is not divorced from mortality. Two reasons the shapes differ, neither implying inertness:
- Dilution into a distal composite. Diabetes is a proximate disease endpoint with a direct mechanism (the muscle glucose «sink»); all-cause mortality is a COMPOSITE of every cause, so a real diabetes reduction moves it only in proportion to diabetes’s share of deaths - the signal is diluted and noisier (and here sits at very-low certainty), not absent.
- Glucose is a SURROGATE. Its transmission to all-cause mortality is imperfect: Look AHEAD improved glycaemia and weight without cutting hard CV events, and intensive glucose-lowering has even raised mortality via hypoglycaemia -> Surrogate Outcomes, Does Weight Loss Reduce Cardiovascular Events.
So clean diabetes, noisy mortality is the expected shape of a diluted, surrogate-mediated distal outcome, not evidence the channel does nothing.